New yellow fever vaccine shows promise in Mid-Stage trial
NCT ID NCT05011123
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study tests a new yellow fever vaccine (vYF) against the current licensed vaccine (Stamaril) in 690 healthy adults aged 18-60 in Europe and Asia. Participants receive one shot, and researchers measure immune response and safety over 5 years. The goal is to see if the new vaccine works as well as the existing one.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
yellow fever vaccine (vYF)
What this could lead to
If successful, this could provide a new, safe, and effective yellow fever vaccine option for adults, potentially improving global vaccine supply.
What could go wrong
This is a Phase 2 trial, so results are still early. The new vaccine may not prove as effective or safe as the existing licensed vaccine, Stamaril.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for YELLOW FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 2460001
Helsinki, 00290, Finland
-
Investigational Site Number : 2460002
Tampere, 33100, Finland
-
Investigational Site Number : 2460003
Turku, 20520, Finland
-
Investigational Site Number : 2500001
Nantes, 44093, France
-
Investigational Site Number : 2500004
Pierre-Bénite, 69495, France
-
Investigational Site Number : 2500006
Montpellier, 34295, France
-
Investigational Site Number : 2500007
Nîmes, 30029, France
-
Investigational Site Number : 2500008
Lyon, 69004, France
-
Investigational Site Number : 2500009
Paris, 75014, France
-
Investigational Site Number : 2760001
Hamburg, 20359, Germany
-
Investigational Site Number : 2760002
München, 80802, Germany
-
Investigational Site Number : 2760003
Rostock, 18057, Germany
-
Investigational Site Number : 2760004
Berlin, 10117, Germany
-
Investigational Site Number : 7020001
Singapore, Singapore
-
Investigational Site Number : 7020002
Singapore, 119074, Singapore
-
Investigational Site Number : 7020003
Singapore, 169608, Singapore
-
Investigational Site Number : 7240001
Barcelona, 08036, Spain
-
Investigational Site Number : 7240002
Madrid, Madrid, Comunidad de, 28046, Spain
-
Investigational Site Number : 7240003
L'Hospitalet de Llobregat, Barcelona [Barcelona], 08907, Spain
-
Investigational Site Number : 7240004
Barcelona, Barcelona [Barcelona], 08035, Spain
-
Investigational Site Number : 7640001
Bangkok, 10330, Thailand
-
Investigational Site Number : 7640002
Bangkok, Thailand
-
Investigational Site Number : 7640003
Nonthaburi, 11000, Thailand